Dr. Jamal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
166 5th Ave
New York, NY 10010Phone+1 212-229-0333Fax+1 646-218-4133
Education & Training
NYU Grossman School of MedicineResidency, Dermatology, 1995 - 1998
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1994 - 1995- New York University School of MedicineClass of 1994
Certifications & Licensure
NY State Medical License 1995 - 2025- American Board of Dermatology Dermatology
Clinical Trials
- ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Start of enrollment: 2020 Feb 18
Publications & Presentations
PubMed
- 181 citationsHIV infection does not require endocytosis of its receptor, CD4.Paul J. Maddon, J. Steven McDougal, Paul R. Clapham, Angus G. Dalgleish, Sumayah Jamal
Cell. 1988-09-09 - 15 citationsEndothelin-1 in the tumor microenvironment correlates with melanoma invasion.Luis Chiriboga, Shane Meehan, Iman Osman, Michael Glick, Gelo de la Cruz
Melanoma Research. 2016-06-01 - 78 citationsUV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cellsSumayah Jamal, Robert J. Schneider
The Journal of Clinical Investigation. 2002-08-15
Press Mentions
9 Dark Spot Treatments That Really Work, According to DermatologistsSeptember 6th, 2019
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in Combination with KEYTRUDA(R) (Pembrolizumab) for Advanced Solid TumorsFebruary 4th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
